Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00901602 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lebanese Interhospital Pneumococcal Surveillance Program

Study acronym: LIPSP
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment target: 300 to 700v6 Show 5 more changesShow less
    • Primary completion date: Oct 2013 to Oct 2030
    • Start date: Oct 2004 to Oct 2005
    • Study completion date: Oct 2014 to Oct 2030
    • Site details revised
    • Collaborators: 1 to 2
  2. Notable Primary completion date: Oct 2010 to Oct 2013v5
  3. Minor Secondary endpoints: details revised at 1 of 1 entryv4
  4. Minor Re-verified, no change to tracked fieldsv3
  5. Minor Primary completion date: Oct 2010v2
  6. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Streptococcus pneumoniae (pneumococcus) is a bacterium that causes severe infections in children and adults such as meningitis, pneumonia, and blood stream infection. There are many types of these bacteria defined by the type of sugar coat that they have. These are classified as serotypes. There are common serotypes that cause severe disease and are preventable by vaccination of children. Other less common types are more difficult to prevent. The investigators aim to determine the serotypes that cause invasive pneumococcal disease in Lebanon and to study their sensitivity to different antibiotics. The investigators will collect bacterial isolates from different hospitals in Lebanon isolated from the blood or spinal fluid of patients with invasive pneumococcal disease. This information will help the investigators determine the usefulness of available pneumococcal vaccines in preventing these infections. The data will be distributed to all primary care physicians treating children in Lebanon and will be shared with the Ministry of Health.
Trial Details
NCT Number NCT00901602
Lead Sponsor American University of Beirut Medical Center
Collaborators: PneumoADIP, Pfizer
Conditions
(from sponsor)
Pneumonia, Meningitis, Sepsis, Bacteremia
Related terms Bacteremia, Meningitis, Pneumonia, Sepsis
Enrollment 700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov